WAY-262611

Research use only, not for human use.

WAY-262611 (WAY262611) is a potent, orally active and Wnt/β-catenin pathway agonist with EC50 of 0.63 nM.

WAY-262611 (WAY262611) is a potent, orally active and Wnt/β-catenin pathway agonist with EC50 of 0.63 nM, via inhibition of dickkopf-1 (DKK-1); increases bone formation rate in ovariectomized rats; inhibits cell migration of fibroblast-like synoviocytes (FLSs) in rheumatoid arthritis.

WAY-262611 has the most potent activity in the primary assay, low kinase inhibition potential, and high solubility.

WAY-262611 has excellent pharmacokinetic properties and shows a dose dependent increase in the trabecular bone formation rate in ovariectomized rats following oral administration. Calvariae from wt mice treated with WAY-262611 shows statistically increased BFR, while similarly treated KO animals are no different from control. This indicates that WAY-262611 is acting via the Wnt β-catenin pathway and most likely through inhibition of Dkk-1.

WAY262611 | WAY 262611

Wnt/Notch/Hedgehog

Dkk-1

Wnt/β-catenin

Other Indications

——

1123231-07-1

318.4155

C20H22N4

>98% (HPLC)

DMSO: ≥ 42 mg/mL

NCC1CCN(C2=NC=CC(C3=CC=C4C=CC=CC4=C3)=N2)CC1.[H]Cl.[H]Cl

4-Piperidinemethanamine, 1-[4-(2-naphthalenyl)-2-pyrimidinyl]-

(-20℃)

With Ice Pack

≥ 2 years